Skip to main content
SpringerLink
Log in

Aktuelle Therapie der polyartikulären Verlaufsform der juvenilen idiopathischen Arthritis

Current therapy of polyarticular forms of juvenile idiopathic arthritis

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Die Polyarthritis ist mit ca. 20 % die dritthäufigste Verlaufsform der juvenilen idiopathischen Arthritis (JIA). Die Polyarthritis ist aber Ursache eines bedeutenden Teils der Krankheitslast und der Langzeitprobleme der JIA. Etablierte Therapieformen mit Steroiden und konventionellen „disease-modifying anti-rheumatic drugs“ (DMARDs) sind in den vergangenen Jahren insbesondere durch die Zulassung neuer Biologika erheblich erweitert worden. Die aktuellen Therapiemöglichkeiten werden hier dargestellt.

Abstract

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in infancy and childhood. Approximately 20 % of patients with JIA suffer from the polyarticular form of the disease, which causes a substantial disease burden and long-term sequelae. Therapeutic approaches have used steroids and conventional disease modifying antirheumatic drugs (DMARD) but over the last decade new drugs have become available for the treatment of JIA, in particular biologic DMARD. This article summarizes the current therapy options for polyarticular JIA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Petty RE et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392

    PubMed  Google Scholar 

  2. Huppertz HI (2011) New criteria for the classification of rheumatoid arthritis: significance for child and adolescent rheumatology? Z Rheumatol 70(5):372–374

    Article  PubMed  Google Scholar 

  3. Adib N et al (2008) Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 47(7):991–995

    Article  CAS  Google Scholar 

  4. Oen KG, Cheang M (1996) Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 26(3):575–591

    Article  CAS  PubMed  Google Scholar 

  5. Greenwald AG et al (2013) Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group? Clin Exp Rheumatol 31(4):645–652

    PubMed  Google Scholar 

  6. Saurenmann RK et al (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56(6):1974–1984

    Article  CAS  PubMed  Google Scholar 

  7. Twilt M et al (2008) Long-term followup of temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Rheum 59(4):546–552

    Article  PubMed  Google Scholar 

  8. Hospach T et al (2014) Cervical spine involvement in patients with juvenile idiopathic arthritis – MRI follow-up study. Pediatr Rheumatol Online J 12:9

    Article  PubMed  PubMed Central  Google Scholar 

  9. Elhai M et al (2013) Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 52(2):267–275

    Article  Google Scholar 

  10. Ringold S et al (2009) Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 48(8):972–977

    Article  Google Scholar 

  11. Ansell BM (1983) Juvenile chronic arthritis with persistently positive tests for rheumatoid factor (sero-positive juvenile rheumatoid arthritis). Ann Pediatr (Paris) 30(8):545–550

    CAS  Google Scholar 

  12. Schanberg LE et al (2005) Pain, stiffness, and fatigue in juvenile polyarticular arthritis: contemporaneous stressful events and mood as predictors. Arthritis Rheum 52(4):1196–1204

    Article  PubMed  Google Scholar 

  13. Sabri K et al (2008) Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS 12(6):539–545

    Article  PubMed  Google Scholar 

  14. Kotaniemi K et al (2001) Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 108(11):2071–2075

    Article  CAS  PubMed  Google Scholar 

  15. Heiligenhaus A et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019

    Article  CAS  Google Scholar 

  16. Angeles-Han ST et al (2013) Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 40(12):2088–2096

    Article  PubMed  PubMed Central  Google Scholar 

  17. Heiligenhaus A et al (2013) Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 21(3):180–191

    Article  PubMed  Google Scholar 

  18. Schmeling H et al (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 66(9):2580–2589

    Article  CAS  PubMed  Google Scholar 

  19. Oen K et al (2003) Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 30(3):585–593

    PubMed  Google Scholar 

  20. Minden K et al (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 51(8):1407–1415

    Article  CAS  Google Scholar 

  21. Huppertz HI, Lehmann HW (2014) Evidence of treatment of chronic inflammation in childhood and adolescence with biologics. Z Rheumatol 73(10):907–916

    Article  CAS  PubMed  Google Scholar 

  22. Beukelman T, Brunner H et al (2016) Chapter 6. In: Petty R, Laxer R (Hrsg) Textbook of pediatric rheumatology. Elsevier, Philadelphia

    Google Scholar 

  23. Guzman J et al (2015) The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 74(10):1854–1860

    Article  PubMed  Google Scholar 

  24. Dueckers G et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176–193

    Article  CAS  PubMed  Google Scholar 

  25. Beukelman T et al (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63(4):465–482

    Article  Google Scholar 

  26. Niehues T (2011) Leitlinien AWMF Register Nr. 027/020

  27. Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294(13):1671–1684

    Article  CAS  PubMed  Google Scholar 

  28. Beukelman T et al (2012) Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 39(9):1867–1874

    Article  PubMed  PubMed Central  Google Scholar 

  29. Giannini EH et al (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 326(16):1043–1049

    Article  CAS  PubMed  Google Scholar 

  30. Alsufyani K et al (2004) The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 31(1):179–182

    CAS  PubMed  Google Scholar 

  31. Ruperto N et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50(7):2191–2201

    Article  CAS  PubMed  Google Scholar 

  32. Céspedes-Cruz A et al (2008) Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 67(3):309–314

    Article  PubMed  Google Scholar 

  33. Albers HM (2009) Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 61:46–51

    Article  CAS  PubMed  Google Scholar 

  34. Savolainen HA et al (1997) Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol 24(12):2444–2450

    CAS  PubMed  Google Scholar 

  35. Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13:118–123

    CAS  PubMed  Google Scholar 

  36. Curtis JR et al (2013) Clinical response within 12 weeks as a predictor of future low disease activity in early RA patients: results from the TEAR Trial. J Rheumatol 40(5):572–578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Silverman E et al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352(16):1655–1666

    Article  CAS  PubMed  Google Scholar 

  38. Ringold S et al (2014) Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 66:1063–1072

    Article  Google Scholar 

  39. Breit W et al (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27(11):2696–2702

    CAS  PubMed  Google Scholar 

  40. Huppertz HI et al (2011) Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatol Int 31(10):1259–1262

    Article  PubMed  PubMed Central  Google Scholar 

  41. Huppertz HI (2011) Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman et al. Arthritis Care Res (Hoboken) 63(9):1354–1355 (author reply 1355–1356)

    Article  Google Scholar 

  42. Lovell DJ et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763–769

    Article  CAS  PubMed  Google Scholar 

  43. Lovell DJ et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58(5):1496–1504

    Article  CAS  PubMed  Google Scholar 

  44. Papsdorf V, Horneff G (2011) Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 50(1):214–221

    Article  CAS  Google Scholar 

  45. Nielsen S et al (2008) Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 26(4):688–692

    CAS  PubMed  Google Scholar 

  46. Horneff G et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519–525

    Article  CAS  PubMed  Google Scholar 

  47. Beukelman T et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773–2780

    Article  PubMed  PubMed Central  Google Scholar 

  48. Toussi SS et al (2013) Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 57(9):1318–1330

    Article  PubMed  PubMed Central  Google Scholar 

  49. McCroskery P et al (2010) Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 14(8):18–26

    Article  Google Scholar 

  50. Beukelman T et al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(4):1263–1271

    Article  PubMed  PubMed Central  Google Scholar 

  51. Simard JF et al (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62(12):3776–3782

    Article  CAS  PubMed  Google Scholar 

  52. Lovell DJ et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820

    Article  CAS  PubMed  Google Scholar 

  53. Brunner H, Ruperto N, Tzaribachev N et al (2014) A148: a multi-center, doubleblind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum 66:S191–S192

    Article  Google Scholar 

  54. Ruperto N et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391

    Article  CAS  PubMed  Google Scholar 

  55. Brunner HI et al (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110–1117

    Article  PubMed  PubMed Central  Google Scholar 

  56. Holzinger D et al (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71(6):974–980

    Article  CAS  PubMed  Google Scholar 

  57. Swart JF, de Roock S, Wulffraat NM (2013) What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther 15(3):213

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Pädiatrische Rheumatologie, Klinikum Stuttgart, Olgahospital, Kriegsbergstr. 62, 70174, Stuttgart, Deutschland

    A. Hospach

  2. Praxis für Kinderheilkunde und Jugendmedizin/Kinderrheumatologie, Göttingen, Deutschland

    J. M. Rühlmann

  3. Prof.-Hess-Kinderklinik, Zentrum für Kinderheilkunde und Jugendmedizin, Klinikum Bremen – Mitte, Gesundheit Nord Klinikverbund Bremen, Bremen, Deutschland

    F. Weller-Heinemann

Authors
  1. A. Hospach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Rühlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Weller-Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Hospach.

Ethics declarations

Interessenkonflikt

T. Hospach: Teilnahme an Advisory Boards der Firmen Novartis, Pfizer, Roche/Chugai, Abbvie. J.M. Rühlmann: Teilnahme an Advisory Boards der Firma Novartis, Vorträge für die Firmen Novartis und Pfizer. F. Weller-Heinemann: Vorträge für die Firmen Novartis, Pfizer, Roche/Chugai und Abbvie.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

H.-I. Huppertz, Bremen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hospach, A., Rühlmann, J.M. & Weller-Heinemann, F. Aktuelle Therapie der polyartikulären Verlaufsform der juvenilen idiopathischen Arthritis. Z Rheumatol 75, 284–291 (2016). https://doi.org/10.1007/s00393-016-0063-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-016-0063-9

Schlüsselwörter

Keywords

Search

Navigation